Open assistant

## AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

[Sign up](/accounts/register/?next=/filings/arctic-bioscience/capitalfinancing-update/2026/33131987/)
[Log in](/accounts/login/?next=/filings/arctic-bioscience/capitalfinancing-update/2026/33131987/)

Sending…

# [Arctic Bioscience](/companies/arctic-bioscience/) — Capital/Financing Update 2026

Apr 1, 2026

Original


Digital View
Digital

### 3536_dirs_2026-04-01_e8c3afc6-552c-49c8-85f4-82839332d41e.html

Capital/Financing Update

[Open in viewer](https://cdn.financialreports.eu/financialreports/media/filings/3536/2026/DIRS/3536_dirs_2026-04-01_e8c3afc6-552c-49c8-85f4-82839332d41e.html)

Opens in your device viewer

Arctic Bioscience - Primary insiders who have provided bank guarantee

# Arctic Bioscience - Primary insiders who have provided bank guarantee

Reference is made to the stock exchange release from earlier today, 1 April 2026

regarding new long-term financing, including agreements with shareholders who

have provided guarantees for the new financing.

The following companies closely related to primary insiders are a part of the

shareholders which have provided guarantees for the new financing:

· Ronja Capital AS, a company closely related to Board Member Tore Tønseth,

NOK 10,0 million

· Vartdal Holding AS, a company closely related to Board Member Jan Endre

Vartdal, NOK 1,5 million

· Brødrene Vartdal AS, a company closely related to Board Member Jan Endre

Vartdal, NOK 1,5 million

This information is subject to the disclosure requirements pursuant to

Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act

§ 5-12.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

### More from Arctic Bioscience

[Declaration of Voting Results & Voting Rights Announcements
2026

May 27](/filings/arctic-bioscience/declaration-of-voting-results-voting-rights-announcements/2026/47455963/)
[AGM Information
2026

May 27](/filings/arctic-bioscience/agm-information/2026/47455938/)
[AGM Information
2026

May 27](/filings/arctic-bioscience/agm-information/2026/47455957/)
[AGM Information
2026

May 27](/filings/arctic-bioscience/agm-information/2026/47455925/)
[Proxy Solicitation & Information Statement
2026

May 13](/filings/arctic-bioscience/proxy-solicitation-information-statement/2026/45468979/)
[Proxy Solicitation & Information Statement
2026

May 13](/filings/arctic-bioscience/proxy-solicitation-information-statement/2026/45468961/)
[Proxy Solicitation & Information Statement
2026

May 13](/filings/arctic-bioscience/proxy-solicitation-information-statement/2026/45468974/)
[Proxy Solicitation & Information Statement
2026

May 13](/filings/arctic-bioscience/proxy-solicitation-information-statement/2026/45468955/)
[Regulatory Filings
2026

May 8](/filings/arctic-bioscience/regulatory-filings/2026/44164841/)
[Regulatory Filings
2026

May 8](/filings/arctic-bioscience/regulatory-filings/2026/44164829/)

[View all filings →](/companies/arctic-bioscience/)